These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 25492271)

  • 1. Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial.
    Shakoor A; Zahoor M; Sadaf A; Alvi N; Fadoo Z; Rizvi A; Quadri F; Tipoo FA; Khurshid M; Sajjad Z; Colan S; Hasan BS
    BMJ Open; 2014 Dec; 4(12):e005360. PubMed ID: 25492271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
    Padhani ZA; Gangwani MK; Sadaf A; Hasan B; Colan S; Alvi N; Das JK
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD011626. PubMed ID: 37975597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
    Sadaf A; Hasan B; Das JK; Colan S; Alvi N
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD011626. PubMed ID: 29998494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial.
    Gupta V; Kumar I; Raj V; Aggarwal P; Agrawal V
    Pediatr Blood Cancer; 2022 Jun; 69(6):e29564. PubMed ID: 35092347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major.
    Khaled A; Salem HA; Ezzat DA; Seif HM; Rabee H
    Drug Des Devel Ther; 2019; 13():2427-2436. PubMed ID: 31413542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial.
    Fernandes JL; Sampaio EF; Fertrin K; Coelho OR; Loggetto S; Piga A; Verissimo M; Saad ST
    Am J Med; 2013 Sep; 126(9):834-7. PubMed ID: 23830536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of magnetic resonance imaging estimation of myocardial iron to left ventricular systolic and diastolic function in thalassemia.
    Leonardi B; Margossian R; Colan SD; Powell AJ
    JACC Cardiovasc Imaging; 2008 Sep; 1(5):572-8. PubMed ID: 19356483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, controlled study evaluating effects of amlodipine addition to chelators to reduce iron loading in patients with thalassemia major.
    Eghbali A; Kazemi H; Taherahmadi H; Ghandi Y; Rafiei M; Bagheri B
    Eur J Haematol; 2017 Dec; 99(6):577-581. PubMed ID: 28960482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.
    Anderson LJ; Westwood MA; Holden S; Davis B; Prescott E; Wonke B; Porter JB; Walker JM; Pennell DJ
    Br J Haematol; 2004 Nov; 127(3):348-55. PubMed ID: 15491298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T2* magnetic resonance and myocardial iron in thalassemia.
    Pennell DJ
    Ann N Y Acad Sci; 2005; 1054():373-8. PubMed ID: 16339685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
    Kumfu S; Chattipakorn SC; Fucharoen S; Chattipakorn N
    Exp Physiol; 2016 Apr; 101(4):521-39. PubMed ID: 26824522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
    Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy.
    Akcay A; Salcioglu Z; Oztarhan K; Tugcu D; Aydogan G; Ayaz NA; Bornaun H; Sen HS; Akici F; Akdana B
    Int J Hematol; 2014 Jun; 99(6):706-13. PubMed ID: 24719246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
    Peng CT; Tsai CH; Wu KH
    Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI monitoring of myocardial iron overload: use of cardiac MRI combined with hepatic MRI in a cohort of multi-transfused patients with thalassaemia.
    Quatre A; Jacquier A; Petit P; Giorgi R; Thuret I
    Diagn Interv Imaging; 2014 Nov; 95(11):1065-9. PubMed ID: 25001363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium Channel Blockers in Conjunction with Standard Iron-Chelating Agents for β-Thalassemia Major: Systematic Literature Search.
    Alali MA; Alanazi KMA; Alsayil SN; Omari Z; Shaaban A
    Hemoglobin; 2020 Nov; 44(6):446-450. PubMed ID: 33430665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major.
    Fernandes JL; Loggetto SR; Veríssimo MP; Fertrin KY; Baldanzi GR; Fioravante LA; Tan DM; Higa T; Mashima DA; Piga A; Coelho OR; Costa FF; Saad ST
    Blood; 2016 Sep; 128(12):1555-61. PubMed ID: 27412888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.